In Vitro Diagnostics Patents

In vitro diagnostics patents cover assay-chemistry innovations; instrument/analyzer innovations; reagent/consumable innovations; and software/algorithm and sample/workflow innovations — with IP held by diagnostics giants and startups (in a field testing samples taken from the body). WHY IN VITRO DIAGNOSTICS: IVD tests are performed on SAMPLES taken FROM the body (blood, urine, tissue, swabs) in a tube or dish ('in vitro' = 'in glass') — as opposed to imaging or testing the patient directly — to DETECT disease, GUIDE treatment, and MONITOR health; IVD is the backbone of medicine (roughly 70% of clinical decisions rely on lab test results) and spans IMMUNOASSAYS (antibody-based tests for proteins/hormones/infections), CLINICAL CHEMISTRY (blood analytes like glucose/cholesterol), MOLECULAR diagnostics (DNA/RNA via PCR/sequencing), HEMATOLOGY, and microbiology — run on automated ANALYZERS in central labs or at the point of care. THE DOMINANT IP REALITY — §101: a biomarker-disease CORRELATION is a NATURAL law/phenomenon, and after the Supreme Court's MAYO and MYRIAD decisions such correlations are generally NOT patent-eligible — so patentable IP lives in the assay CHEMISTRY, the INSTRUMENT, the REAGENTS/consumables, software, and workflow, NOT the correlation; moreover, IVD is largely a RAZOR/RAZORBLADE business (an analyzer plus recurring proprietary reagents) and a REGULATORY (FDA clearance, laboratory-developed-test/LDT rules) game, where reagent lock-in and clearance matter as much as patents. MAJOR HOLDERS: ROCHE, ABBOTT, SIEMENS HEALTHINEERS, DANAHER, THERMO FISHER, plus diagnostics startups. Assay chemistry, instrument/analyzer, reagent/consumable, software/algorithm, and sample/workflow are the core IVD patent domains — with §101 (Mayo/Myriad) the gate, and assays, instruments, reagents, software, and workflow the patentable whitespace.

Assay-chemistry innovations; instrument/analyzer innovations; detection innovations; and §101-aware claiming represent core IVD patent domains — and the test chemistry and the analyzer are the foundational, patentable capabilities (the natural correlation is not). ASSAY-CHEMISTRY PATENTS: the biochemical TEST and its signal — IMMUNOASSAY formats (sandwich/competitive, chemiluminescence, ELISA), CLINICAL-CHEMISTRY reactions, MOLECULAR assays (PCR/qPCR, isothermal, sequencing-based), and the reagents, labels, and detection chemistry; assay-chemistry methods are core, high-value IP (a concrete assay/detection chemistry is man-made technology, clearly §101-eligible — unlike the natural correlation it measures), with a specific NOVEL detection method or treatment-selection method claimable. INSTRUMENT / ANALYZER PATENTS: the automated ANALYZER that runs many samples at scale — FLUIDICS/liquid handling, sample/reagent automation, DETECTION systems (optics, electrochemistry, mass spec), and high-throughput design; instrument/analyzer methods are core, high-value IP (the analyzer is the durable, capital instrument in the razor/razorblade model and clearly-patentable engineering — a faster, more-automated, more-sensitive analyzer is a major asset). DETECTION PATENTS: sensitive/specific detection technologies (single-molecule, digital PCR, advanced labels) improving limits of detection; detection methods are high-value IP. §101-AWARE CLAIMING: NEVER claim the biomarker-disease correlation (Mayo/Myriad) — claim the assay, a novel detection method, the instrument, the reagent, or a treatment method; §101-aware claiming is THE threshold skill for IVD IP. Assay chemistry, instrument/analyzer, detection, and §101-aware claiming are the highest-value core IP because concrete test chemistry and automated analyzers are exactly what is patentable in a field where the underlying correlation is not.

Reagent/consumable innovations; software/algorithm innovations; sample/workflow innovations; and multiplex/panel innovations represent additional IVD patent domains — and the recurring reagents, the interpretation software, and the lab process are where the business model and additional patentable value lie. REAGENT / CONSUMABLE PATENTS: the proprietary REAGENTS, cartridges, calibrators, controls, and consumables that the analyzer uses — the RECURRING-REVENUE razorblade; reagent/consumable compositions/methods are core, high-value IP (proprietary reagents create lock-in (the analyzer only runs your reagents) and recurring revenue — the reagents are a clearly-patentable, business-critical asset, often the real economic moat). SOFTWARE / ALGORITHM PATENTS: result COMPUTATION, CALIBRATION, quality control, and interpretation/scoring algorithms (including AI for image-based or complex results); software/algorithm methods are high-value IP BUT §101-SENSITIVE (claim a specific technical implementation/improvement to the diagnostic system, not abstract 'analyze data' or the natural correlation). SAMPLE / WORKFLOW PATENTS: SAMPLE collection/stabilization/preparation/extraction and the LAB WORKFLOW/AUTOMATION (sample tracking, total lab automation, turnaround); sample/workflow methods are PATENTABLE, valuable IP (man-made processes, clearly §101-eligible, and real operational differentiators). MULTIPLEX / PANEL PATENTS: MULTIPLEX assays measuring many analytes at once and combining them into panels/signatures; multiplex/panel methods are high-value IP (multiplexing and panels are commercially valuable and offer system-level claims). Reagent/consumable, software/algorithm, sample/workflow, and multiplex/panel are the highest-value application IP because proprietary reagents, interpretation software, lab process, and multiplex panels are exactly what make an IVD commercially valuable — claimed around §101.

IVD startup IP strategy must navigate the §101 Mayo/Myriad constraint (the #1 issue — biomarker-disease correlations are natural laws and NOT patent-eligible; NEVER rely on correlation claims; build IP on the assay, instrument, reagents, novel detection methods, software (as systems), and workflow), the razor/razorblade business model (IVD is fundamentally an instrument + recurring proprietary REAGENT business — the reagent lock-in and recurring revenue are often a bigger moat than patents, and reagents are clearly patentable), the regulatory moat (FDA clearance/approval, and the laboratory-developed-test (LDT) pathway, are major commercial gates and non-patent moats — and FDA's evolving LDT oversight shapes strategy), the giant-incumbent landscape (Roche/Abbott/Siemens/Danaher dominate with deep IP and installed analyzer bases — do thorough FTO, and consider whether to sell on others' analyzers or build your own), the platform-vs-test distinction (the analyzer PLATFORM is reusable instrument IP; specific tests/assays are product IP — both matter), the software/§101 sensitivity (diagnostic software/AI must be claimed as technical systems), the installed-base lock-in (analyzers create captive reagent demand — placing instruments is a strategic moat), and a landscape where assays, instruments, reagents, software, and workflow are the durable assets; understand that correlations are §101-barred, so the durable IP is in assay chemistry, instruments/analyzers, proprietary reagents/consumables, novel detection, software (as systems), and workflow — with reagent lock-in, FDA clearance, the analyzer install base, and proprietary chemistry often the real moat (not patents), and that §101-survivable claiming, reagent lock-in, FDA clearance, clinical validity, and instrument placement matter as much as patents; identify whitespace in assays, detection, reagents, multiplex panels, and workflow. IVD STARTUP IP STRATEGY: ASSAY CHEMISTRY, INSTRUMENT/ANALYZER, REAGENTS/CONSUMABLES, NOVEL DETECTION/SOFTWARE (AS SYSTEMS), AND WORKFLOW ARE THE IP: patent the assay chemistry, instrument/analyzer, proprietary reagents/consumables, novel detection, software (as technical systems), and sample/workflow — NOT the natural correlation; §101 (MAYO/MYRIAD) IS THE #1 GATE: biomarker-disease correlations are natural laws/products and ineligible — NEVER claim the correlation; claim the assay/instrument/reagent/novel-detection/treatment method (claim drafting is everything); RAZOR/RAZORBLADE IS THE BUSINESS MODEL + A MOAT: IVD is an analyzer (razor) + recurring proprietary REAGENTS (razorblades) — reagent lock-in and recurring revenue are often a bigger moat than patents (and reagents are clearly patentable); REGULATORY (FDA/LDT) IS A COMMERCIAL GATE + NON-PATENT MOAT: FDA clearance/approval and the LDT pathway are major gates and protective moats — and evolving LDT oversight shapes strategy; INCUMBENTS DOMINATE WITH INSTALLED ANALYZER BASES — DO FTO + DECIDE PLATFORM: Roche/Abbott/Siemens/Danaher hold deep IP and captive install bases — clear FTO; decide whether to run on others' analyzers or build your own; PLATFORM (ANALYZER) VS TEST (ASSAY): the analyzer is reusable platform IP; specific tests are product IP — both matter; INSTALLED-BASE LOCK-IN IS STRATEGIC: analyzers create captive reagent demand — placing instruments is a moat; SOFTWARE/AI IS §101-SENSITIVE: claim diagnostic software/AI as technical systems, not abstract analysis; §101/REAGENT-LOCK-IN/FDA/CLINICAL-VALIDITY/INSTALL-BASE MATTER AS MUCH AS PATENTS: §101-survivable claiming, reagent lock-in, FDA clearance, clinical validity, and instrument placement drive value; WHEN TO PATENT (OR RELY ON REAGENT/REGULATORY MOATS): NOVEL ASSAY/INSTRUMENT/REAGENT/DETECTION WITH MEASURED PERFORMANCE: file (and secure reagent/regulatory moats) once a test shows measured results (analytical/clinical validity — sensitivity/specificity + limit of detection + throughput/turnaround + §101-survivable claim framing) — analytical/clinical validity, reagent lock-in, and §101-survivable claiming are the critical IVD IP metrics; KEY FTO CHECKLIST: Roche/Abbott/Siemens Healthineers/Danaher/Thermo Fisher; §101 Mayo/Myriad (NEVER the correlation; claim assay/instrument/reagent/detection/treatment method); assay chemistry (immunoassay/clinical chemistry/molecular-PCR/sequencing, labels/detection); instrument/analyzer (fluidics/automation/detection/throughput); reagent/consumable (proprietary reagents/cartridges/calibrators — razorblade/lock-in); detection (single-molecule/digital PCR/sensitive labels); software/algorithm (computation/calibration/interpretation/AI — claim as system); sample/workflow (collection/prep/extraction/lab automation); multiplex/panel; FDA clearance/LDT pathway; analyzer install-base moat.